News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Teladoc trades near $5.11 with ~$909M market cap and $166.9M free cash flow, making a tactical long candidate.
  • Eli Lilly's Foundayo approval boosts its obesity franchise, while pricing pressure and execution risks threaten near-term margins.
  • Analyst recommends long entry at $940.06, stop at $880, and target $1,150 on Eli Lilly.
  • President Trump said U.S. forces are clearing the Strait of Hormuz and that Iranian minelaying vessels have been sunk.
  • U.S. and Iranian representatives began talks in Islamabad hosted by Pakistan under a fragile ceasefire.
  • Strait developments could increase volatility in shipping and oil markets.

Latest Articles

Anebulo Pharmaceuticals Shares Dive After Board Votes to Exit Nasdaq

Anebulo Pharmaceuticals Shares Dive After Board Votes to Exit Nasdaq

Anebulo Pharmaceuticals Inc. (NASDAQ: ANEB) saw its shares fall sharply after the company announced plans to voluntarily delist from the Nasdaq Capital Market and deregister its common stock with the SEC. The board said costs of maintaining public reporting status outweigh the benefits, and the company will file paperwork in mid-February 2026 to ma…

UBS Sticks With Buy on AppFolio, Holds $260 Price Target After Q4 Results

UBS Sticks With Buy on AppFolio, Holds $260 Price Target After Q4 Results

UBS retained its Buy rating on AppFolio (APPF) and kept a $260.00 price target after reviewing the company’s fourth-quarter results and a subsequent management call. The bank highlighted robust unit growth and management’s positive tone as reasons for optimism, while noting that revenue may lag unit expansion as AppFolio moves upmarket. The stock i…

Truist Lifts Reddit Price Target to $275 Following Strong Q4 2025 Results

Truist Lifts Reddit Price Target to $275 Following Strong Q4 2025 Results

Truist Securities increased its price objective for Reddit to $275 from $270 and reaffirmed a Buy rating after the company posted robust fourth-quarter 2025 results. The quarter delivered 70% year-over-year revenue growth and a 43% AEBITDA margin, and the company announced a $1 billion share repurchase program. Other sell-side firms issued divergen…

Zillow Shares Jump After Judge Allows Listing Rule to Stay in Place

Zillow Shares Jump After Judge Allows Listing Rule to Stay in Place

Zillow Group's stock climbed after a federal judge refused Compass Inc.'s bid to temporarily block Zillow's rule that requires listings to be posted to a local multiple-listing service within 24 hours of being marketed elsewhere. The ruling permits Zillow to keep enforcing the policy as Compass's antitrust lawsuit, filed in June, moves forward, mar…

Morgan Stanley trims Kering target as Gucci's rebound shows early weakness

Morgan Stanley trims Kering target as Gucci's rebound shows early weakness

Morgan Stanley cut its price target on Kering to €315 from €370, citing a slower-than-expected start to 2026 for the luxury group and renewed doubts over the pace of Gucci's turnaround. The bank trimmed sales forecasts for 2026 and 2027 and said it lowered earnings estimates across the 2026-28 cycle, while keeping an Overweight rating given longer-…

Bernstein SocGen Lifts Cummins Price Target to $600 After Mixed Q4 Results

Bernstein SocGen Lifts Cummins Price Target to $600 After Mixed Q4 Results

Bernstein SocGen Group increased its price target on Cummins to $600 from $544 and kept a Market Perform rating after the engine maker's fourth-quarter results. The quarter delivered an earnings beat and slightly stronger EBITDA, but guidance that included lower margin expectations sent the stock down 11%, even as the company outlined modest sales …

Bernstein SocGen Cuts Boston Scientific Target After EP Sales Shortfall

Bernstein SocGen Cuts Boston Scientific Target After EP Sales Shortfall

Bernstein SocGen has reduced its 12-month price target for Boston Scientific to $112 from $130 but retained an Outperform rating following a weaker-than-expected quarter in U.S. electrophysiology sales. The company’s Q4 EP revenue of $606 million fell short of the $643 million consensus, coinciding with an 18% slide in the stock amid heightened inv…